[1] Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in can-cer immune evasion and potential therapeutic implications[J]. Curr Opin Immunol, 2012, 24(2):225-232. [2] Brown EJ, Frazier WA. Integrin-associated protein(CD47)and its ligands[J]. Trends Cell Biol, 2001, 11(3):130-1355. [3] Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis[J]. Cell, 2009, 138:271-285. [4] Sarfati M, Fortin G, Raymond M, et al. CD47 in the immune response:Role of thrombospondin and sirp-alpha reverse signaling[J]. Curr Drug Targets, 2008, 9(10):842-850. [5] Poels LG, Peters D, van MY, et al. Monoclonal antibody against human ovarian tumor associated antigens[J]. J Natl Cancer Inst, 1986, 76:781-791. [6] Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia[J]. Cancer Res, 2011, 71:1374-1384. [7] Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma[J]. Cell, 2010, 142:699-713. [8] Rendtlew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma[J]. Br J Haematol, 2007, 138:756-760. [9] Chan KS, Espinosa I, Chao MP, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells[J]. Proc Natl Acad Sci, 2009, 106:14016-14021. [10] Willingham SB, Volkmer JP, Gentles AJ. The CD47-signal regulatory protein alpha(SIRPa)interaction is a therapeutic target for human solid tumors[J]. Proc Natl Acad Sci, 2012, 109(17):6662-6667. [11] Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains[J]. Nature, 1993, 363(6428):446-448. [12] Serge M. Nanobodies:Natural single-domain antibodies[J]. Annual Review of Biochemistry, 2013, 82:17.1-17.23 [13] De GE, Silence K, Decanniere K, et al. Molecular basis for the preferential cleft recognition by dromedary heavy- chain antibodies[J]. Proc Natl Acad Sci USA, 2006, 103(12):4586-4591. [14] Zhao XW, Taco WK, Timo KB. targeting of CD47-SIRP? Enough for treating hematopoietic malignancy[J]. BLOOD, 2012, 119:18. [15] Daley LP, Gagliardo LF, Duffy MS, et al. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids[J]. Clin Diagn Lab Immunol, 2005, 12(3):380-386. [16] Barclay AN, Van den Berg TK. The interaction between Signal Regulatory Protein Alpha(SIRPα)and CD47 structure, function, and therapeutic target[J]. Annu Rev Immunol, 2013, 32:25-50. [17] Lauwereys M, Ghahroudi MA, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies[J]. EMBO J, 1998, 17:3512-3520. |